PréMont Marie-Claude, Gagnon Marc-André
Professeure titulaire, École nationale d'administration publique (ENAP), Montréal, QC.
Assistant Professor, School of Public Policy and Administration, Carleton University, Ottawa, ON.
Healthc Policy. 2014 Nov;10(2):79-89.
The recent restructuring of the pharmaceutical industry has led to three new types of promotional strategies to build patient loyalty to brand name drugs: loyalty through rebates, patient support, and compassion programs. Loyalty through rebates seeks to keep patients on a brand name drug and prevent their switch to the generic equivalent. Loyalty through patient support provides aftersales services to help and support patients (by phone or home visits) in order to improve adherence to their treatments. Finally, compassion programs offer patients access to drugs still awaiting regulatory approval or reimbursement by insurers. When and if the approval process is successful, the manufacturer puts an end to the compassion program and benefits from a significant cohort of patients already taking a very expensive drug for which reimbursement is assured. The impact of these programs on public policies and patients' rights raises numerous concerns, among which the direct access to patients and their health information by drug manufacturers and upward pressure on costs for drug insurance plans.
制药行业最近的重组催生了三种新型促销策略,旨在培养患者对品牌药的忠诚度:通过回扣、患者支持和关爱计划实现忠诚度。通过回扣实现忠诚度旨在让患者持续使用品牌药,防止他们转而使用通用等效药。通过患者支持实现忠诚度提供售后服务,通过电话或家访帮助和支持患者,以提高他们对治疗的依从性。最后,关爱计划让患者能够使用仍在等待监管批准或保险公司报销的药物。当且如果批准程序成功,制造商就会终止关爱计划,并从一大批已经在服用一种非常昂贵且报销有保障的药物的患者中受益。这些计划对公共政策和患者权利的影响引发了诸多担忧,其中包括制药商直接接触患者及其健康信息以及对药品保险计划成本的上行压力。